Moderna’s Uncertain Future: A Medical Mirage or Sustainable Success?
The demand for Moderna’s COVID-19 vaccine, once a savior of society, began to wane as the world gradually resumed its routine. Hospitals, once overwhelmed by the urgency of the pandemic, resumed their normal operations, while the chorus of anti-vaccine rhetoric gained strength. The world had moved on, and with it, the revenue streams that had once flowed so abundantly. Today, the company still receives income from its vaccine, but it is but a shadow of its former self-a mere fraction of the lofty figures from 2021.